The potential roles of osmotic and non-osmotic sodium handling in mediating effects of SGLT2 inhibitors on heart failure

Petter Bjornstad, Peter J. Greasley, David C. Wheeler, Glenn M. Chertow, Anna Maria Langkilde, Hiddo J.L. Heerspink, Daniël H. van Raalte

PII: S1071-9164(21)00291-8
DOI: https://doi.org/10.1016/j.cardfail.2021.07.003
Reference: YJCAF 4830

To appear in: Journal of Cardiac Failure

Received date: 9 February 2021
Revised date: 8 June 2021
Accepted date: 2 July 2021

Please cite this article as: Petter Bjornstad, Peter J. Greasley, David C. Wheeler, Glenn M. Chertow, Anna Maria Langkilde, Hiddo J.L. Heerspink, Daniël H. van Raalte, The potential roles of osmotic and non-osmotic sodium handling in mediating effects of SGLT2 inhibitors on heart failure, Journal of Cardiac Failure (2021), doi: https://doi.org/10.1016/j.cardfail.2021.07.003

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2021 Published by Elsevier Inc.
Title: The potential roles of osmotic and non-osmotic sodium handling in mediating effects of SGLT2 inhibitors on heart failure

Short title: Sodium & HF outcomes of SGLT2i

Petter Bjornstad, Peter J. Greasley, David C. Wheeler, Glenn M. Chertow, Anna Maria Langkilde, Hiddo J.L. Heerspink, and Daniël H. van Raalte

University of Colorado Anschutz Medical Campus and Children’s Hospital Colorado, Aurora, CO, USA; BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; Department of Renal Medicine, University College London, London, UK; The George Institute for Global Health, Sydney, Australia; Division of Nephrology, Department of Medicine, Stanford University School of Medicine, Palo Alto, CA, USA; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; Diabetes Center, Department of Internal Medicine, Amsterdam University Medical Center, location VUMC, Amsterdam, The Netherlands

*Corresponding author information:

Daniël van Raalte, M.D., Ph.D.
Amsterdam University Medical Center, location VUMC
De Boelelaan 1117, 1081 HV
Amsterdam, The Netherlands
Highlights

- SGLT2 inhibitors (SGLT2i) mitigate CKD progression and HF hospitalization
- Sodium regulation may contribute to SGLT2i’s cardioprotective mechanisms
- SGLT2i might mitigate HF via effects on non-osmotic sodium storage

Abstract word count: 199200
Manuscript word count: 407469

Abbreviations

AKI, acute kidney injury; BP, blood pressure; CKD, chronic kidney disease; ECV, extracellular volume; ESL, endothelial surface layer; GFR, glomerular filtration rate; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; MRI, magnetic resonance imaging; NHE3, Na+/H+ exchanger isoform 3; PWV, pulse wave velocity; RAAS, renin–angiotensin–aldosterone system; SGLT1, sodium-glucose cotransporter 1; SGLT2, sodium-glucose cotransporter 2; T2D, type 2 diabetes.
Concomitant type 2 diabetes and chronic kidney disease (CKD) increases the risk of cardiovascular disease (CVD), including heart failure (HF). Renoprotective agents, while decreasing fluid overload and blood pressure and improving endothelial function and vascular tone, may protect against CVD and HF. Conversely, glucose lowering drugs modestly ameliorate CVD risk and possibly even worsen HF outcomes. Recent studies demonstrate beneficial effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on CKD progression and HF hospitalization, and other cardiovascular outcomes, in patients with and without diabetes. The underlying mechanisms are incompletely explained by modest improvements in blood pressure, glycemic control, body weight, and serum urate. In addition to inhibiting glucose reabsorption, SGLT2i reduce proximal tubular sodium reabsorption, possibly leading to transient natriuresis. We review the hypothesis that SGLT2i's natriuretic and osmotic diuretic effects of SGLT2i mediate their cardio-protective effects. The degree to which these benefits are related to changes in sodium, independent of the kidney, is currently unknown. Aside from effects on osmotically active sodium, we explore the intriguing possibility that SGLT2i could also modulate non-osmotic sodium storage. This alternative hypothesis is based on emerging literature that challenges the traditional two-compartment model of sodium balance to provide support for a three-compartment model that includes the binding of sodium to glycosaminoglycans, such as those in muscles and skin. Recent research on non-osmotic sodium storage, as well as and direct cardiac effects of SGLT2i, provides possibilities for other ways in which SGLT2i inhibitors might contribute to their benefits in mitigate HF risk. Overall, we review explore the effects of SGLT2i on sodium balance and sensitivity, cardiac tissue, interstitial fluid and plasma volume, and non-osmotic sodium storage.
Keywords: Heart failure, Natriuresis, Non-osmotic sodium, SGLT2 inhibitors
Introduction

Type 2 diabetes (T2D) is an established risk factor for ischemic cardiovascular disease (CVD) and heart failure (HF). (1) The risks of ischemic CVD and HF are increased with albuminuria and/or impaired kidney function. Although in recent decades cardiovascular outcomes have improved for adults with or without T2D, reducing the burden associated with HF by treating classical cardiovascular risk factors has proven to be difficult and thus remains a major public health priority. (2) Accordingly, the introduction of sodium-glucose cotransporter (SGLT) 2 inhibitors offers promise to mitigate cardiorenal disease in people with or without T2D. However, to better understand the role of these drugs in the cardiovascular system, it is important to define their mechanism of action on the cardiorenal axis.

The kidney contributes to glucose homeostasis by actively reabsorbing nearly all of the filtered glucose in the proximal tubule. Although the kinetics of renal glucose reabsorption were first described nearly 90 years ago, it took until the early 1970s to demonstrate that glucose reabsorption occurs in the proximal tubule through two distinct sodium-glucose cotransport systems. Shortly thereafter, two sodium-glucose cotransporters (SGLT1 and SGLT2) were discovered. (3) SGLT1 is a high-affinity, low-capacity transporter responsible for approximately 10% of the renal glucose reabsorption; SGLT2 is a low-affinity, high-capacity transporter responsible for approximately 90% of the renal glucose reabsorption. (4, 5) Together, these transporters are thought to be responsible for total renal glucose reabsorption. In addition to glucose reabsorption, SGLT1 and SGLT2 also facilitate concomitant sodium reabsorption. Approximately two-thirds of the total kidney sodium reabsorption occurs in the proximal tubule, although the extent to which this reabsorption is mediated by SGLT1 and SGLT2 presently remains unknown. (6)

SGLT2 inhibitors were granted marketing authorization in 2014 as glucose-lowering drugs, and work by inducing glucosuria. Through their mechanism of action, the
glucose-lowering effects of SGLT2 inhibitors in patients with chronic kidney disease (CKD) are modest. However, these drugs have recently received considerable attention in large cardiovascular safety trials owing to favorable HF and renal benefits (Figure 1). For example, in patients with T2D and high CVD risk, the EMPA-REG OUTCOME trial demonstrated a 35% relative risk reduction in hospitalization for HF for empagliflozin versus placebo, while the CANVAS Program with canagliflozin demonstrated beneficial cardiovascular and renal outcomes. The CRESCEND trial, which studied the effects of canagliflozin in patients with T2D and diabetic kidney disease, reported a reduction in HF hospitalization by 39% (95% CI 20%–53%), in addition to attenuating loss of kidney function. Given the strong link between CKD and HF, this further emphasizes the importance of the cardiorenal axis. By comparison, studies assessing the cardiovascular effects of glucose lowering per se, when mediated by other agents, had not demonstrated similar benefits, while HF outcomes may even be worsened by some glucose-lowering drugs.

Since publication of the results of several of these and other cardiovascular safety trials (Figure 1), as well as real-world effectiveness studies (e.g., CVD-REAL), investigators and clinicians have considered a variety of potential mechanisms underlying the cardiorenal benefits of SGLT2 inhibition. It is generally agreed that (modest) reductions in blood pressure (BP), glucose concentrations, body weight, and serum urate concentrations do not fully explain the observed cardiovascular benefits. Although the exact pathways are not fully understood, the purpose of this article is to describe the effects of SGLT2 inhibitors on sodium handling beyond diuresis and natriuresis per se, and to discuss the proposed cardiovascular consequences of changes in sodium sensitivity and balance, including direct sodium-related cardiac effects, effects on interstitial fluid and plasma volume, and changes in non-osmotic sodium storage.
Figure 1 Summary of hospitalization for heart failure results from recent cardiovascular safety trials of SGLT2 inhibitors.

Values in brackets are 95% confidence intervals. Values were derived from the trials’ publications; slightly different terminology was used in the trials to describe heart failure hospitalization: EMPA-REG and DECLARE used “rate per 1000 pt-yrs”, CANVAS used “number of participants per 1000 pt-yrs”, and CREDENCE and DAPA-HF used “events per 1000 [or 100 for DAPA-HF] pt-yrs”.

CANVAS, CAnagliflozin cardioVascular Assessment Study; CREDENCE, Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation; DAPA-HF, Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure; DECLARE, Dapagliflozin Effect on Cardiovascular Events–Thrombolysis in Myocardial Infarction 58; EMPA-REG, EMPAgliflozin
cardiovascular outcome event trial in type 2 diabetes mellitus patients—Removing Excess Glucose; HR, hazard ratio; SGLT2, sodium-glucose cotransporter 2; yrs, years.

Sodium balance, sodium sensitivity, and cardiovascular health

Given the well-known role of sodium in cardiovascular health, we next address recent research that challenges traditional views about sodium homeostasis, with potential implications for the pathophysiology and treatment of HF, including the pathophysiological role of interstitial sodium in HF, as reviewed elsewhere. (16) In most adult populations, the average salt intake well exceeds the ~5-g daily limit recommended by the World Health Organization.(17) Excessive salt intake has been linked to hypertension, CVD,(18) and CKD. Although the pathogenesis underlying the relationship between excessive salt intake and cardiorenal complications remains debated, the leading hypothesis for decades has been that—in so-called salt-sensitive individuals—excess sodium intake with concomitant impaired renal sodium excretion results in extracellular volume (ECV) expansion and hypertension.(19) Particularly in patients with CKD, lower glomerular filtration rate (GFR) reduces the rate of sodium and fluid excretion, possibly leading to and activation of the renin–angiotensin–aldosterone system (RAAS) result in and, consequently, through various mechanisms, leads to reduced cardiac output, elevated venous pressure, reduced renal perfusion, reduced cardiac output, and ultimately HF. The net results of these pathophysiological changes include further sodium and water retention with activation of the RAAS and the sympathetic nervous system. However, carefully designed sodium-balance studies in so-called ‘salt-resistant’ participants, i.e., individuals in whom increased salt intake does not increase BP or body water/weight, show that much of the ingested sodium excess is in fact not excreted in the urine.(20) Rather, these studies have proposed that sodium may be stored non-osmotically (i.e., without altering ECV) at extrarenal locations, which serve to act as an osmotic sodium buffer. For example, daily rhythmic fluctuations in total body sodium
content were found with large variations in 24-hour urinary sodium excretion, despite a fixed sodium intake, which suggests non-osmotic sodium accumulation and the storage of salt in a third body compartment. (20) Osmotic excretion of significant amounts of sodium has also been shown in healthy people after hypertonic saline infusion. (21) Using $^{23}$Na magnetic resonance imaging (MRI), muscle and skin were shown to contain considerable amounts of sodium without associated water retention. (22) Another compartment that binds sodium in a non-osmotic manner and thus could influence ECV and BP regulation is the endothelial surface layer (ESL), or glycocalyx, located on the luminal side of the vascular endothelium. The ESL has abundant negatively charged glycosaminoglycans and is in direct contact with circulating blood sodium and glucose. These glycosaminoglycans have been shown to display avid sodium-binding capacity. (23) Emerging literature has challenged the traditional two-compartment model of sodium balance providing support to a three-compartment model that includes the binding of sodium to glycosaminoglycans, such as those in the muscles and skin. ESL damage has been observed in patients with T2D (24) and CKD, (25) which could explain (at least in part) the salt sensitivity observed in this population. Other functions of the ESL include production of nitric oxide due to shear stress and formation of a barrier to prevent circulating inflammatory cells from reaching underlying tissues. Consistent with these data, restoration of the ESL by sulodexide, a mixture of ESL constituents, has been shown to reduce BP. (26)

Although non-osmotic sodium storage seems beneficial in the short term, saturated sodium depots in the skin have been linked to both hypertension and left ventricular hypertrophy. (27) Additionally, high versus low dietary sodium intake has been shown to increase the number of monocytes, (28) which could trigger an inflammatory response. Furthermore, inflammation of the interstitium might drive microvascular and macrovascular stiffening and possibly impair endothelial function. (29)
Non-osmotic buffering of sodium in tissues, such as glycocalyx, may reduce the adverse hemodynamic effects of sodium in the short term, although longstanding sodium overload may have deleterious consequences for the cardiovascular system. For example, some evidence suggests that sodium accumulation in the endothelial glycocalyx could lead to arterial stiffness.(30) Accordingly, strategies to reduce tissue and interstitial sodium by facilitating renal sodium excretion may enhance cardiovascular health, although we stress that the concept of non-osmotic sodium storage remains theoretical, while efforts are undertaken to more definitively determine its presence and role. We next discuss other mechanisms behind the putatively central role of sodium in mediating the favorable cardiorenal effects of SGLT2 inhibition.

Effects of SGLT2 inhibitors on sodium balance
While SGLT2 inhibitors were primarily designed to lower plasma glucose concentrations, it is evident that there is concomitant inhibition of proximal tubular sodium uptake with the inhibition of glucose reabsorption. Data showing inhibition of lithium reabsorption, as a marker for proximal tubular function, support this notion.(31) However, studies of proximal tubular sodium absorption have not been conducted in people with HF. Initial natriuresis is thought to contribute to the osmotic diuresis, which drives the increased urine output associated with acute SGLT2 inhibition, as shown in some(32, 33) but not all studies.(31) The placebo-controlled RECEDE-CHF trial conducted in patients with T2D and HF demonstrated a significant increase in 24-hour urine volume without an increase in urinary sodium concentration when empagliflozin was used in combination with a loop diuretic.(34) While RECEDE-CHF did not find a significant increase in the fractional excretion of sodium with empagliflozin, another study did.(32) A difference possibly explainable by the different time points studied between the two studies as well as differences in sodium intake at baseline.
Notably, the major limitation of current studies showing natriuresis with SGLT2 inhibition is that study participants were not on a fixed-sodium diet. The DAPASALT study, by contrast, was conducted in patients (N=17) with T2D and preserved kidney function on a fixed-sodium diet. The study participants received dapagliflozin and had 24-hour urine collected prior to treatment, after acute dosing, after 2 weeks of treatment, and 3 days after treatment cessation, but changes in natriuresis or plasma volume were not found. Whereas the bulk of sodium is reabsorbed in the proximal tubule, it is unclear to what extent SGLT2 transporters contribute to total sodium reabsorption in absolute terms. This phenomenon may be particularly relevant in people with T2D, in whom there is increased glucose flux through the SGLT2 transporters due to chronic tubular hyperglycemia. It is likely that SGLT2 transporters also interact functionally with Na⁺/H⁺ exchanger isoform 3 (NHE3) in the proximal tubule (Figure 2).

**Figure 2** Schematic of a nephron and SGLT inhibitors.
NHE3, Na⁺/H⁺ exchanger isoform 3; SGLT, sodium-glucose cotransporter; SGLT2, sodium-glucose cotransporter 2.

As such, SGLT2 inhibition is associated with marked inhibition of NHE3, even in the absence of glucose, which is likely to account for a significant proportion of the natriuresis observed with agents of this class. Another study (conducted in various animal models and human cells) did not find that SGLT2 inhibition with empagliflozin inhibited the ubiquitously expressed plasma membrane Na⁺/H⁺ exchanger NHE1, however. Limited data exist describing proximal sodium reabsorption in humans with T2D before and during SGLT2 inhibitor therapy. The kidneys rapidly adapt to the initial natriuresis by matching sodium excretion to sodium intake, maintaining a neutral sodium balance. Therefore, sodium excretion is usually not altered with prolonged treatment likely because of compensatory sodium reabsorption at more distal tubular segments. Where the additional sodium is being absorbed remains unclear. Any increase in renal sodium absorption induced by SGLT2 inhibition is likely distal to the macula densa, as the decline in estimated GFR induced by SGLT2 inhibition through tubuloglomerular feedback is thought to be driven by increased sodium and chloride concentrations detected by the macula densa. Sodium balance is restored rapidly, and owing to blockade of sodium absorption proximally, there is increased delivery of sodium to the macula densa. Gene expression analyses of key sodium transporters located in the distal tubule could expand knowledge of these compensatory pathways in humans.

The natriuresis and osmotic diuresis associated with SGLT2 inhibition has been shown in some studies to be associated with a modest reduction in plasma volume, although a study of canagliflozin treatment found this reduction to be attenuated at week 12. The reduction in plasma volume is reflected by an increase in hematocrit and radioactive-labeled albumin which is sustained during prolonged treatment, but is reversed after cessation of
therapy. A mathematical model-based analysis to assess the fluid effects of dapagliflozin and the loop diuretic bumetanide was recently reported, based on data acquired in a healthy volunteer study of these two drugs.\(^{(40, 41)}\) A key finding of this analysis was that a similar reduction in interstitial volume occurred in response to dapagliflozin as compared to that observed with bumetanide, but a smaller reduction was observed in plasma volume, which may result in improved tissue perfusion and less acute kidney injury (AKI) incidence with SGLT2 inhibition compared with loop diuretics. Such studies highlight the differences between SGLT2 inhibitors and loop diuretics. However, the hypothesis that SGLT2 inhibitors reduce interstitial volume is based on modeling assumptions, and not on direct measurements. Further, although the mechanism by which SGLT2 inhibitors reduce interstitial volume is not known, osmotic diuresis resulting from increased urinary glucose excretion might lead to more electrolyte-free water clearance.\(^{(32, 44)}\) Possibly because of their different site of action in the tubular system, these drug classes have markedly different effects on potassium, uric acid, glucose, renal hemodynamics, and markers of the RAAS (Figure 3).\(^{(40, 41)}\) SGLT2 inhibitors have consistently been shown to modestly increase renin levels due to their diuretic/natriuretic effect.\(^{(45)}\) Reductions in interstitial fluid volume may contribute to the cardiovascular benefits observed in recent cardiovascular safety trials, particularly vis-à-vis HF.\(^{(46)}\) A mediation analysis of the EMPA-REG OUTCOME trial found that change in hematocrit explained 51.8% of the effect of empagliflozin versus placebo on the risk of cardiovascular death.\(^{(14)}\)

Increased higher hematocrit has also been observed in patients with T2D without HF\(^{(47, 48)}\) and in patients with HF with reduced ejection fraction (HFrEF) (in which 42% had a history of diabetes at baseline).\(^{(49)}\)

**Figure 3** Plasma renin activity with SGLT2 inhibition. (A) Increase in plasma renin activity by 117% after 1 week of bumetanide treatment in healthy volunteers (adapted from: Wilcox et
Week 12 change from baseline in plasma renin activity in patients with T2D treated with DAPA or HCTZ (based on data from: Heerspink et al. 2013, Table 2); (C) Changes in plasma volume markers during DAPA treatment versus placebo treatment in patients with T2D; $P<0.01$ (adapted from: Eickhoff et al. 2019, Figure 2, fourth panel from the left; available at: https://www.mdpi.com/2077-0383/8/6/779; used under CC BY 4.0, text slightly updated, layout altered, and color added). (50)

DAPA, dapagliflozin; HCTZ, hydrochlorothiazide; SGLT2, sodium-glucose cotransporter 2; T2D, type 2 diabetes.

Changes in hematocrit could reflect hemodynamic changes related to plasma volume contraction, which may reduce ventricular filling pressures and cardiac workload. (14, 43) It is
unclear whether the beneficial HF outcomes are partly because of a direct increase in hematocrit or attributable to factors underlying the increase in hematocrit, although the latter is more likely. Changes in hematocrit are unlikely to be explained by changes in plasma volume alone. The natriuretic response induced by SGLT2 inhibitors might restore the physiologic tubuloglomerular feedback, thus lowering intraglomerular pressure, as stated above. (51) Changes in kidney physiology could then lead to changes in renal oxygen metabolism that affect erythropoietin production, although this remains speculative. An increase in erythropoiesis, resulting from a decrease in distal tubular oxygen content secondary to increased workload, could contribute to the rise in hematocrit and could be a marker of a beneficial action of these agents given that increased erythropoietin levels may contribute to improved myocardial oxygen delivery. (47) It is partly through this possible sequence of events that SGLT2 inhibitors could benefit the heart. Treatment with dapagliflozin has been shown to suppress hepcidin levels. (52) Given that SGLT2 inhibition has been shown to reduce adipose tissue inflammation in a murine model of obesity, (53) this also raises the intriguing possibility that SGLT2 inhibition might reduce hepcidin levels via an anti-inflammatory effect, subsequently improving anemia associated with HFrEF. The effects of SGLT2 inhibitors on interstitial fluid and circulatory volumes should be confirmed, and downstream effects explored, to better understand their cardio-protective mechanisms.

Aside from inducing changes in osmotically active sodium, SGLT2 inhibitors could also modulate non-osmotic sodium storage, although less evidence is available to support this hypothesis in this area. (40) In a porcine model of HF, empagliflozin reduced skin sodium content and interstitial fluid volume to a greater extent than did furosemide. (54) Karg and colleagues explored this hypothesis in a study in which 51 participants with T2D were treated with dapagliflozin or placebo for 6 weeks. Sodium content in the skin and muscles of the lower leg was measured by $^{23}$Na-MRI. (55) Serum sodium, 24-hour urinary sodium...
excretion, and muscle sodium content were not significantly changed at 6 weeks by dapagliflozin treatment; however, skin sodium content was reduced. Similar studies in patients with CKD, who commonly manifest extracellular volume overload, should be conducted.

In summary, SGLT2 inhibitors were initially designed to reduce tubular glucose reabsorption, thereby lowering serum glucose and glycosylated hemoglobin. However, SGLT2 inhibitors might also induce a natriuretic response associated with diuresis, with a more pronounced effect on interstitial fluid compared with plasma volume. Natriuresis is unlikely to completely explain the benefits of SGLT2 inhibition, since it is transient (i.e., likely present in the first 24 hours after first dosing) and modest when compared with diuretics,(33) and recent findings may even call for re-examination of this hypothesis.(31) Accordingly, other consequences of SGLT2-inhibitor–induced alterations in sodium handling, i.e., changes in systemic hemodynamics and the vascular system, as well as potential non-osmotic sodium storage, may also contribute to the observed cardiovascular benefit (Figure 4).

**Figure 4** Putative sodium-centric mechanisms of benefit of SGLT2 inhibitors in people with T2D and cardiorenal disease.
BP, blood pressure; T2D, type 2 diabetes; SGLT2, sodium-glucose cotransporter 2.
Effects of SGLT2 inhibition on arterial stiffness and endothelial function

SGLT2 inhibition demonstrates durable BP reduction, which may partly account for their cardiorenal benefits and may be partly driven by reductions in body sodium content.(8, 9, 56) SGLT2 inhibitors have also been shown to reduce arterial stiffness and improve endothelial function. Arterial stiffness, determined largely by the elastin-to-collagen ratio in the vessel wall, is associated with the risk for cardiovascular events. Accordingly, noninvasive measures of central and peripheral arterial stiffness can serve as useful surrogate markers to determine the effectiveness of pharmacotherapies in improving cardiovascular health.(57)

Arterial stiffness, measured by pulse wave velocity (PWV), decreased in response to 8 weeks of empagliflozin 25 mg in an open-label, prospective clinical trial in young adults with type 1 diabetes mellitus.(58) Consistent with these data, a post hoc analysis from phase 3 trials in adults with T2D demonstrated reduced arterial stiffness, as assessed by pulse pressure and ambulatory arterial stiffness index, and arterial resistance as measured by mean arterial pressure, in response to empagliflozin.(59) In a pilot study in 16 adults with T2D, two days of dapagliflozin 12.5 mg was shown to increase flow-mediated dilatation and to reduce PWV and renal resistive index, independent of BP reductions.(60) These data suggest that the effects of SGLT2 inhibition on systemic and renal vascular stiffness and on endothelial dysfunction are acute and persistent. Empagliflozin or dapagliflozin also restore nitric oxide production by human endothelial cells, which may contribute to the beneficial effects of SGLT2 inhibition on endothelial function, although such results were not in vivo and used high empagliflozin concentrations (1 µM).(61, 62) In vivo data from a porcine model of patients with HF without diabetes indicate that empagliflozin improves NO signaling and diastolic function.(63) An additional post hoc analysis of pooled data from four phase 3 studies demonstrated that canagliflozin attenuated pulse pressure and mean arterial pressure in
adults with T2D. Finally, trials have also demonstrated improvement in endothelial function by reactive hyperemia peripheral arterial tonometry and flow-mediated dilatation in response to dapagliflozin in adults with T2D. The mechanisms by which SGLT2 inhibition reduces arterial stiffness and improves endothelial dysfunction are not fully understood but may be related to changes in sodium exposure. The effect of SGLT2 inhibition on arterial stiffness is particularly relevant to the endothelial glycocalyx, which, as noted above, functions as a non-osmotic sodium buffer and which can be damaged by sodium and glucose overload.

Direct sodium-related cardiac effects of SGLT2 inhibition
The full mechanisms of action of SGLT2 inhibition remain incompletely understood. Given the potentiating effect of increased myocardial intracellular sodium concentrations in HF, various lines of research have investigated the direct effects of SGLT2 inhibitors on the heart in vitro model systems. Direct effects of SGLT2 inhibition on sodium concentrations in cardiomyocytes have been identified, independent of systemic effects produced via the kidney, which is remarkable given the absence of SGLT2 receptors in the heart. For example, empagliflozin was shown to decrease cardiac cytoplasmic sodium concentration via cardiac NHE inhibition. Apart from sodium-mediated effects, other direct effects, reviewed elsewhere, are possibly also involved in the long-term cardio-protective effects of SGLT2 inhibitors, but are beyond the scope of the present article review.

Moving from mechanisms to clinical outcomes
As briefly stated, SGLT2 inhibition has yielded remarkable effects on cardiovascular (particularly HF) and kidney renal outcomes in large clinical trials (Figure 1).
These results were confirmed in cardiovascular safety trials in patients with T2D and established CVD or at high risk for cardiovascular events in the DECLARE-TIMI 58(56) and CANVAS(9) studies, which also demonstrated improvement in HF outcomes without previous documented HF or established CVD at baseline. Since echocardiography was not routinely performed to assess ejection fraction in these cardiovascular safety trials, any differential effect of SGLT2 inhibitors on patients with HF with preserved or reduced ejection fraction merits further study. Based on the beneficial HF findings in cardiovascular safety trials, dedicated HF trials were designed to characterize the effects of SGLT2 inhibition in preventing adverse outcomes in patients with HF. In the DEFINE-HF study, treatment with dapagliflozin indeed reduced symptoms and improved the quality of life in 263 patients with HF and reduced ejection fraction (HFrEF) with or without T2D, despite no significant reduction in levels of N-terminal pro b-type natriuretic peptide.(73) In the DAPA-HF trial, which recruited 4744 patients with or without T2D with New York Heart Association class II, III, or IV HF and ejection fraction ≤40%, dapagliflozin reduced the primary endpoint consisting of a composite of cardiovascular death or worsening HF (hospitalization or an urgent visit resulting in intravenous therapy for HF) by 26% (95% CI 15%–35%).(72) No differences were observed between individuals with or without diabetes.(72) (74) First, confirmation of beneficial effects in patients with HFrEF has come from the EMPEROR-Reduced study, which investigated the effects of empagliflozin on HF outcomes in patients with or without diabetes.(74) Reverse left ventricular remodeling with SGLT2 inhibition has also been demonstrated in patients with HFrEF with (75) or without T2D.(76) The CREDENCE trial, which studied the effects of canagliflozin in patients with T2D and diabetic kidney disease(62) reported a reduction in HF hospitalization by 39% (95% CI 20%–53%), in addition to attenuating loss of kidney function. Given the strong link between CKD and HF, this further emphasizes the importance of the cardiorenal axis.(62)
The limited effect of SGLT2 inhibitors on atherothrombotic disease (11% reduction in MACE in a recent meta-analysis(77)), and the strong effects on HF and kidney outcomes with early divergence of group outcomes (benefits seen after 3 months), strongly point to a hemodynamic effect that relates to sodium balance as postulated here. The fact that SGLT2 inhibitors improve HF outcomes to the same extent in patients with HFrEF and without diabetes is the strongest argument to date that these beneficial effects are completely glucose independent.

Several studies that might support or refute these hypotheses are currently ongoing. First, confirmation of beneficial effects in patients with HFrEF has come from the EMPORER-Reduced study, which investigated the effects of empagliflozin on HF outcomes, in patients with or without diabetes.(77) Second, the DELIVER (dapagliflozin; NCT03619213) and EMPORER-Preserved (empagliflozin; NCT03057951) studies investigate whether the reduction in HF hospitalization extends to patients with HF with preserved ejection fraction and with normal or near normal kidney function (without albuminuria) these benefits of HF hospitalization extend to people with HF with preserved ejection fraction. The phase 3 DAPA-CKD trial, which was stopped early based on overwhelming efficacy, reported a hazard ratio for the composite of death from cardiovascular causes or hospitalization for HF of 0.71 (95% CI 0.55–0.92; P=0.009) as well as benefit on kidney outcomes, in patients with CKD with and without diabetes.(71) Third, studies such as DAPACARD (NCT03387683) and ERADICATE-HF (NCT03416270) investigate the underlying mechanisms, focusing on myocardial substrate metabolism, sodium reabsorption, and plasma volumes.

**Conclusion**
The recently introduced class of glucose-lowering SGLT2 inhibitors has received much attention because of their remarkable yet largely unexpected cardiorenal benefits, in particular with respect to prevention and treatment of HF. Comprehensive understanding of the mechanisms underlying these benefits currently remains elusive and is subject to ongoing investigations. It is evident that glucose lowering per se, as well as reductions in BP and plasma volume or increases in hematocrit, do not fully explain the cardiovascular benefits. It has been proposed that protection may occur via both metabolic (cardiorenal metabolism and substrate utilization) and non-metabolic effects. This review has summarized data on the salutary effects of SGLT2 inhibition unrelated to glucose metabolism, including changes in sodium balance, sodium sensitivity, and direct sodium effects on the heart and non-osmotic sodium stores, and hypothesized that these may partly contribute to improved HF outcomes. Importantly, however, data correlating either changes in extracellular sodium stores or direct cardiac effects with clinical outcomes are not yet available. Moreover, despite some support, the non-osmotic sodium hypothesis is novel and remains to be fully validated. Better understanding of the non-osmotic mechanisms underpinning the cardiorenal benefits of SGLT2 inhibition may allow researchers to assess the effects of SGLT2 inhibitors in combination with other drugs that affect sodium.
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have cardiovascular benefits that include heart failure outcomes in patients with and without diabetes. As the underlying mechanisms are only partly explained by improvements in blood pressure, body weight, or glucose control, other mechanisms have been proposed. We focus here on a central role for effects on sodium as underlying the positive benefits of SGLT2i in heart failure. We explore the new (though still unconfirmed) idea that SGLT2i exert some of their positive effects by affecting non-osmotic sodium (i.e., sodium bound to muscles and skin and not dissolved in the blood).

- SGLT2i have emerged as a class of drugs, previously prescribed for patients with type 2 diabetes, that have in more recent years been shown to have substantial heart and kidney clinical benefits in patients with and without type 2 diabetes
- The degree to which these benefits are related to kidney-independent changes in sodium homeostasis is currently unknown
- Better understanding of the non-osmotic mechanisms underpinning the benefits of SGLT2 inhibition on heart failure (with reduced or preserved left ventricular ejection fraction) may allow researchers to assess the effects of SGLT2i in combination with other treatments that affect sodium balance
Legend: Sodium may occupy a central role in the many mechanisms by which SGLT2 inhibitors might benefit people with heart failure.
Role of funding sources: This work was supported by the Dutch Diabetes Foundation and EU Marie Curie program [research fellowship to DHvR]. This work was also supported by the National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases [grant number K23 DK116720-01; salary and research support to PB] and additionally, by the Thrasher Research Fund; the Juvenile Diabetes Research Foundation; the National Institute of Diabetes and Digestive and Kidney Diseases/Diabetic Complications Consortium; the International Society of Pediatric and Adolescent Diabetes; the Colorado Clinical & Translational Sciences Institute; and the Center for Women’s Health Research at University of Colorado [research support to PB].

Acknowledgments: Editorial assistance was provided by Steven Tresker and Varun Kumar Pandey, PhD, both of Cactus Life Sciences (part of Cactus Communications), which was supported by AstraZeneca.

Author contributions: The authors were fully responsible for all content and editorial decisions and have approved the final version. All authors were involved in conceptualization and writing review/editing. PB and DHvR wrote the original draft.

Disclosure: HJLL serves as a consultant for AbbVie, AstraZeneca, Boehringer Ingelheim, CSL Pharma, Fresenius, Gilead, Janssen, Merck, Mitsubishi Tanabe, Mundipharma, and Retrophin. PB has acted as a consultant for Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Horizon Pharma, Novo Nordisk, and Sanofi, and serves on the advisory board of XORTX. DHvR has acted as a consultant and received honoraria from Boehringer Ingelheim and Eli Lilly, Merck, Novo Nordisk, and Sanofi and has received research operating funds from AstraZeneca, Boehringer Ingelheim-Eli Lilly Diabetes Alliance, MSD, and Novo
Nordisk. GMC has served as a consultant to AstraZeneca and has received research support from Janssen. DCW has acted as a consultant and/or received honoraria from Astellas, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Janssen, Napp, Mitsubishi Tanabe, Mundipharma, and Vifor Fresenius. PJG and AML are employees and shareholders of AstraZeneca.
References


28


35. Pessoa TD, Campos LC, Carraro Lacroix L, Girardi AC, Malnic G. Functional role of glucose metabolism, osmotic stress, and sodium-glucose cotransporter isoform-mediated...


